Recombinant live-attenuated human metapneumovirus vaccine (NIAID)

N/A

Report date: 2022/11/27 13:48:51

Base Information

Drug NameRecombinant live-attenuated human metapneumovirus vaccine (NIAID)

Drug Alias NamerHMPV-ParhMPVrhMPV-R 329K

ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Live attenuated vaccineVaccines > Biological material > Viral vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsMetapneumovirus infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)

China Registration ClassN/A

Develop Information

Active CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)

Inactive CompaniesN/A

Active IndicationsMetapneumovirus infections

Inactive IndicationsN/A

Other Information

ATC CodeN/A